Cellebrite's stock price plummeted 5.05% during intraday trading on Thursday, reflecting significant selling pressure on the shares.
The sharp decline followed news that Needham had cut its price target for Cellebrite DI Ltd to $18 from $24, representing a substantial 25% downward revision that signaled reduced analyst confidence in the company's valuation prospects.